Retlaw Enterprises
Retlaw Enterprises
| Type | Private |
|---|---|
| Industry | Entertainment |
| Products | Intellectual property management |
Retlaw Enterprises was a private company founded by Walt Disney in 1952. The name "Retlaw" is "Walter" spelled backwards, reflecting the personal touch Walt Disney incorporated into many of his projects. Retlaw Enterprises was primarily involved in the management of intellectual property rights for Disney family-owned aspects of the larger Disney Corporation.
History
Retlaw Enterprises was established to manage certain assets that were personally owned by Walt Disney, separate from the Walt Disney Company. This included the ownership of the Disneyland Railroad and the Monorail System, which were significant attractions at the Disneyland park in Anaheim, California. The company also held rights to Walt Disney's name and likeness.
In the 1980s, as part of a restructuring and consolidation process within the Disney family's holdings, the assets of Retlaw Enterprises were gradually integrated into the Walt Disney Company. This move was part of an effort to streamline operations and unify the branding and management of Disney properties.
Operations
The primary operations of Retlaw Enterprises included the licensing of Walt Disney's name and image, as well as the operation of transportation systems within Disneyland. The company played a crucial role in the development and expansion of Disneyland by managing these unique assets, which were critical to the park's identity and appeal.
Impact on Disney Legacy
Retlaw Enterprises had a significant impact on the legacy of Walt Disney. By maintaining control over key personal and family-owned assets, the company ensured that Walt Disney's personal vision continued to influence the development and operation of Disneyland. Moreover, the management of these assets by Retlaw Enterprises helped to preserve the distinctiveness of the Disney brand, which is characterized by a close association with its founder.
See Also
.svg){kind=small}
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
